{"entity":{"id":"paper-anbl0532-tandem-transplant-park-jama-2019","kind":"paper","name":"ANBL0532: tandem versus single autologous stem cell transplant for high-risk neuroblastoma","aka":[],"tldr":"Two consecutive high-dose chemotherapy courses with stem cell rescue improved three-year event-free survival compared with a single transplant in high-risk neuroblastoma, and the gain was largest in children who went on to receive anti-GD2 immunotherapy.","summary":"Children's Oncology Group phase 3 trial of 652 children with high-risk neuroblastoma, of whom 355 were randomised after induction to single transplant (carboplatin-etoposide-melphalan) or tandem transplant (thiotepa-cyclophosphamide followed by carboplatin-etoposide-melphalan).\n\nThree-year event-free survival was 61.6 versus 48.4 percent; overall survival did not differ significantly (74.1 versus 69.6 percent); among patients receiving immunotherapy, event-free survival was 73.7 versus 56.0 percent.","asOf":"2026-09-17","links":[{"label":"JAMA 2019","url":"https://doi.org/10.1001/jama.2019.11642"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31454045/"}],"tags":[],"related":[],"cancers":["neuroblastoma-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["anbl0532"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama"],"dependsOn":[],"notes":[],"journal":"JAMA","year":2019,"doi":"10.1001/jama.2019.11642","pmid":"31454045","authors":"Park JR, Kreissman SG, London WB, et al.","paperType":"rct","findings":["Three-year event-free survival 61.6 percent vs 48.4 percent.","With post-consolidation immunotherapy: 73.7 percent vs 56.0 percent."],"whatItMeans":"Tandem transplant is the standard consolidation in North American protocols for high-risk neuroblastoma; Europe uses single busulfan-melphalan.","caveats":["Only about half of enrolled patients reached randomisation.","No significant overall survival benefit."],"changedPractice":true,"participants":355},"route":"/key-papers/paper-anbl0532-tandem-transplant-park-jama-2019/","neighbours":{"cancer":[{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"}],"trial":[{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/"}],"journal":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/"}]}}